Servier plans to buy Day One Biopharmaceuticals, maker of the pediatric brain tumor drug OJEMDA, for about $2.5 billion.[1] Day One Biopharmaceuticals has projected net product sales revenue of $155.4 million in 2025, an increase of 172 percent over the previous year.[1] The company issued more than 4,600 prescriptions for OJEMDA in 2025, an increase of more than 180 percent from 2024.[2] For 2026, Day One projects OJEMDA revenues between $225 and $250 million.[1][2] The company ended 2025 with approximately $441 million in net cash and no debt.[2] The acquisition of Mersana, which closed in January 2026, expanded Day One's portfolio with the new cancer drug Emi-Le (emiltatug ledadotin).[2]